Literature DB >> 9846914

Collagen-derived markers of bone metabolism in osteogenesis imperfecta.

A M Lund1, M Hansen, G Kollerup, A Juul, B Teisner, F Skovby.   

Abstract

Markers of bone formation [C-terminal and N-terminal propeptides of procollagen I (PICP, PINP), osteocalcin and alkaline phosphatase] and bone resorption [C-terminal cross-linked telopeptide of collagen I (ICTP) and hydroxypyridinium cross-links, pyridinoline (Pyr) and deoxypyridinoline (Dpyr)] were measured in 78 osteogenesis imperfecta (OI) patients to investigate bone metabolism in vivo and relate marker concentrations to phenotype and in vitro collagen I defects, as shown by sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE). PICP and PINP were generally low, and the serum levels were lower in all children and adults with mild OI and a quantitative collagen defect than in patients with severe OI and a qualitative collagen I defect. ICTP, Pyr and Dpyr were generally normal or reduced, but elevated in severely affected adults with a qualitative collagen I defect. The in vivo findings correlated with in vitro results of collagen I SDS-PAGE. Bone turnover is reduced in OI children and mildly affected OI adults, whereas bone resorption is elevated in severely affected adults. These findings may prove helpful for diagnosis and decision-making regarding therapy in OI.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9846914     DOI: 10.1080/080352598750031112

Source DB:  PubMed          Journal:  Acta Paediatr        ISSN: 0803-5253            Impact factor:   2.299


  9 in total

1.  [Osteogenesis imperfecta].

Authors:  M Salzmann; C Krohn; N Berger
Journal:  Orthopade       Date:  2014-08       Impact factor: 1.087

2.  Ulmus davidiana extract improves lumbar vertebral parameters in ovariectomized osteopenic rats.

Authors:  Xinming Zhuang; Changfeng Fu; Wanguo Liu; Yuanyi Wang; Feng Xu; Qi Zhang; Yadong Liu; Yi Liu
Journal:  Am J Transl Res       Date:  2016-02-15       Impact factor: 4.060

Review 3.  Osteogenesis imperfecta: practical treatment guidelines.

Authors:  F Antoniazzi; M Mottes; P Fraschini; P C Brunelli; L Tatò
Journal:  Paediatr Drugs       Date:  2000 Nov-Dec       Impact factor: 3.022

4.  Cellular mechanism of decreased bone in Brtl mouse model of OI: imbalance of decreased osteoblast function and increased osteoclasts and their precursors.

Authors:  Thomas E Uveges; Patricia Collin-Osdoby; Wayne A Cabral; Felicia Ledgard; Leah Goldberg; Clemens Bergwitz; Antonella Forlino; Philip Osdoby; Gloria A Gronowicz; Joan C Marini
Journal:  J Bone Miner Res       Date:  2008-12       Impact factor: 6.741

5.  Impaired pyridinoline cross-link formation in patients with osteogenesis imperfecta.

Authors:  Kosei Hasegawa; Kyoko Kataoka; Masaru Inoue; Yoshiki Seino; Tsuneo Morishima; Hiroyuki Tanaka
Journal:  J Bone Miner Metab       Date:  2008-07-04       Impact factor: 2.626

6.  Current and emerging treatments for the management of osteogenesis imperfecta.

Authors:  Elena Monti; Monica Mottes; Paolo Fraschini; Piercarlo Brunelli; Antonella Forlino; Giacomo Venturi; Francesco Doro; Silvia Perlini; Paolo Cavarzere; Franco Antoniazzi
Journal:  Ther Clin Risk Manag       Date:  2010-09-07       Impact factor: 2.423

7.  Bone mass, bone markers and prevalence of fractures in adults with osteogenesis imperfecta.

Authors:  Lena Lande Wekre; Erik F Eriksen; Jan A Falch
Journal:  Arch Osteoporos       Date:  2011-04-14       Impact factor: 2.617

8.  Osteogenesis Imperfecta with Celiac Disease and Type II Diabetes Mellitus Associated: Improvement with a Gluten-Free Diet.

Authors:  Luis Rodrigo; Isabel Pérez-Martinez
Journal:  Case Rep Med       Date:  2012-03-05

Review 9.  Osteogenesis Imperfecta.

Authors:  Justin Easow Sam; Mala Dharmalingam
Journal:  Indian J Endocrinol Metab       Date:  2017 Nov-Dec
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.